| Literature DB >> 27718211 |
C S Hakkers1, J E Arends2, R E Barth2, S Du Plessis3, A I M Hoepelman2, M Vink4.
Abstract
HIV-associated neurocognitive disorder (HAND) is a frequently occurring comorbidity of HIV infection. Evidence suggests this condition starts subclinical before a progression to a symptomatic stage. Blood oxygenated level dependent (BOLD) fMRI has shown to be a sensitive tool to detect abnormal brain function in an early stage and might therefore be useful to evaluate the effect of HIV infection on brain function. An extensive literature search was performed in June 2015. Eligibility criteria for included studies were as follows: (1) conducting with HIV-positive patients, (2) using BOLD fMRI, and (3) including a HIV-negative control group. A total of 19 studies were included in the review including 931 participants. Differences in activation between HIV-positive and -negative participants were found when testing multiple domains, i.e., attention, (working) memory, and especially executive functioning. Overall, HIV-positive patients showed hyperactivation in task-related brain regions despite equal performances as controls. Task performance was degraded only for the most complex tasks. A few studies investigated the effect of aging on fMRI, and most of them found no interaction with HIV infection. Only three studies evaluated the effect of combination antiretroviral therapy (cART) on functional data suggesting an increase in activation with the use of cART. fMRI is a sensitive instrument to detect subtle cognitive changes in HIV patients. Open questions remain regarding the effects of cART on fMRI and the effects of aging on fMRI.Entities:
Keywords: BOLD; HAND; Systematic review; fMRI
Mesh:
Substances:
Year: 2016 PMID: 27718211 PMCID: PMC5329077 DOI: 10.1007/s13365-016-0483-y
Source DB: PubMed Journal: J Neurovirol ISSN: 1355-0284 Impact factor: 2.643
Fig. 1Process of study selection. BOLD blood oxygenated level dependent, fMRI functional MRI
Baseline characteristics
| Author | Correlated NPA | No. | Mean age (SD) | % male | Years of education (SD) | Impaired cognition | substance abuse | Co-medication | % on cART | Type of cART | Duration of cART | Mean current CD4 (IQR) | Mean nadir CD4 (IQR) | Duration infection | No sign. difference on | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caldwell ( | No | HIV+ | 34 | 46.1 (8.5) | 54 | 12.6 (1.8) | NR | 0 | NR | 79 | NR | NR | 550 | 201 | 7.6 years | Age sex |
| HIV− | 28 | 44.9 (12.7) | 65 | 14.0 (3.4) | NR | 0 | NR | |||||||||
| Thomas ( | Yes | HIV+ | 52 | 41 (14) | 90 | 14 (2) | 23 % impairment | 25 % | NR | 44 | NR | NR | 377 (291–616) | 260 (116–386) | NR | Age |
| HIV− | 52 | 44 (14) | 51 | 15 (3) | NR | NA | NR | |||||||||
| Ances ( | Yes | HIV+ | 6 | 30 (7) | 100 | 15 (2) | GDS 0.34 | 16 % | NR | 83 | NR | NR | 757 (424–900) | 588 (438–750) | NR | Age sex education |
| HIV− | 10 | 30 (6) | 60 | 18 (3) | NR | 0 | NR | |||||||||
| Ernst ( | Yes | HIV+ | 31 | 49.6 (8.4) | 97 | 15.5 (2.2) | NR | 0 | No neuro-impairing medication | 100 | NR | NR | 415 (40.4) | 152 (24) | NR | Age sex education hematocrit |
| HIV− | 32 | 46.9 (13) | 88 | 15.5 (2.3) | NR | 0 | No neuro-impairing medication | |||||||||
| Melrose ( | Yes | HIV+ | 11 | 40.8 (7.1) | 100 | 16.3 (1.5) | 9 % mild impairment | 9 % alcohol | 36.4 % anti-depressant | 91 | NR | 9.9 (5.4) years | 694.2 (197) | NR | 9.9 (5.4) years | Age sex education |
| HIV− | 11 | 40.9 (8.7) | 100 | 16.9 (1.8) | 0 | 9 % alcohol | 0 | |||||||||
| Chang ( | Yes | HIV+ | 66 | 47.1 (8.6) | 100 | 14.6 (2.3) | 43.90 % HAND | 0 | NR | NR | NR | NR | 401.7 | 158.4 | 144.22 months | Age sex education hematocrit |
| HIV− | 56 | 45.7 (12.7) | 100 | 14.8 (2.2) | 0 | 0 | NR | |||||||||
| Ances ( | Yes | HIV+ | 24 | 45.5 (6.9) | 71 | 14.5 (3.5) | GDS 0.95 of 7 MND en 8 HAD | 0 | NR | 100 | 1* | 20 months | 368 | NR | >1 year | Age sex education |
| HIV− | 10 | 46 (12.6) | 60 | 14 (3.2) | GDS 0.3 | 0 | NR | |||||||||
| Chang ( | Yes | HIV+ | 24 | 40.15 (8.1) | 100 | 13.7 (2.6) | GCD art+:6.2(0.2) art−:6.0(0.9) | 0 | No neuro-impairing medication | 50 | 2* | 134.8 (21.7) months | 467.5 | 218.5 | 129.9 months | Age sex education hematocrit |
| HIV− | 18 | 39.82 (12.3) | 100 | 13.9 (2.1) | GCD 2.7(0.5) | 0 | No neuro-impairing medication | |||||||||
| Juengst ( | Yes | HIV+ | 31 | 47.7 (15.7) | 90 | 14.5 (2.7) | 35 % MNCD or HAD | NR | NR | NR | NR | NR | 397.41 | NR | NR | None |
| HIV− | 16 | 42.3 (11.8) | 75 | 14.0 (3.0) | NR | NR | NR | |||||||||
| Ernst ( | Yes | HIV+ | 10 | 36.3 (7.9) | 100 | 14.8 (2.0) | 0 | 20 % smoking | NR | 90 | 3* | NR | 375 (187) | 241 (145) | NR | Age sex education |
| HIV- | 10 | 36.1 (6.8) | 100 | 15.6 (2.6) | 0 | 20 % smoking | NR | |||||||||
| Chang ( | No | HIV+ | 11 | 41 (4.8) | 100 | 14 (2.1) | 36 % MCMD 27 % mild HIV-dementia | 0 | NR | 91 | 4* | NR | 329 (197) | 170 (126) | NR | Age sex education |
| HIV− | 11 | 38 (4.8) | 100 | 16.4 (3.3) | 0 | 0 | NR | |||||||||
| Maki et al. ( | Yes | HIV+ | 7 | 41.1 | 0 | 11.7 | NR | 29 | NR | 43 | NR | NR | NR | NR | NR | Age sex education |
| HIV− | 4 | 42.8 | 0 | 12.3 | NR | 50 | NR | |||||||||
| Chang ( | Yes | HIV+ | 18 | 38.2 (7) | 78 | 14.2 (1.6) | 55 % MCMD 33 % mild dementia | 0 | No chronic co-medication | 83.3 | PI-regime | 27.7 weeks | 287 (36) | 123 (37) | 91 (15) months | Age sex education hematocrit |
| HIV− | 18 | 38.0 (8.8) | 78 | 14.5 (1.9) | 0 | 0 | No chronic co-medication | |||||||||
| Castelo ( | Yes | HIV+ | 14 | 39 (9.1) | 100 | 14.8 (2.0) | 0 | 0 | 5* | 71 | NR | NR | 690 (370) data from 10 out of 14 patients | NR | NR | Age sex education |
| HIV− | 14 | 40 (10.4) | 100 | 16 (1.9) | 0 | 0 | 5* | |||||||||
| Ances ( | No | HIV+ | 26 | 39 | 77 | 16 | NR | 0 | NR | 60 | NR | At least 3 months | 486 | 278 | NR | Age sex education |
| HIV− | 25 | 41 | 56 | 15 | NR | 0 | NR | |||||||||
| Schweinsburg ( | No | HIV+ | 11 | 41.8 (6.1) | 82 | 13.9 (2.4) | NR | 0 | NR | 91 | NR | NR | NR | 140 (29–300) | NR | Age sex education |
| HIV− | 13 | 42.5 (14.5) | 77 | 14.9 (2.1) | NR | 0 | NR | |||||||||
| du Plessis ( | Yes | HIV+ | 18 | 32 (4.6) | 11 | 11 (10–12)6* | GDS 0.21 | 0 | NR | 0 | NA | NA | 433 (199) | NR | NR | Age sex education |
| HIV− | 16 | 28 (5.2) | 6 | 12 (11–12)6* | GDS 0.17 | 0 | NR | |||||||||
| Ipser et al. ( | Yes | HIV+ | 15 | 40.6 (14.5) | 80 | 13.8 (2.2) | GDS 0.32 (0.28) | Alcohol 13.3 % | NR | 86 | NR | NR | 548 (255.29) | 310 (193) | 80.4 months | Age sex education |
| HIV− | 15 | 39.7 (12.6) | 87 | 13.7 (1.3) | GDS0.29 (0.26) | Alcohol 46.7 % | NR | |||||||||
| Ortega et al. ( | Yes | HIV+ | 131 | 39.0 | 72 | 13.1 |
| NR | NR | 63 | NR | NR | 551 | 281 | NR | Sex education |
| HIV− | 45 | 31.7 (10.9) | 58 | 13.4 (2.7) |
| NR | NR |
cART combination antiretroviral therapy, CD4 CD4-cell count, GCD global cognitive deficit, GDS global deficit score, HAD HIV-associated dementia, HIV+ HIV-positive, HIV− HIV-negative, IQR interquartile range, MCMD minor cognitive motor disorder, NA not applicable, NPA neuropsychological assessment, NR not reported, SD standard deviation
*(low CPE, high CPE) protease inhibitor 50 %, 42 %; nucleoside reverse transcriptase inhibitor 66 %, 83 %; non-nucleoside reverse transcriptase inhibitor 33 %, 42 %
°8 tenofovir, 5 lamivudine, 3 zidovudine, 2 abacavir, 1 didanosine, 1 stavudine, 2 emtricitabine, 4 efavirenz, 2 nevirapine, 3 lopinavir/ritonavir, 2 ritonavir, 1 saquinavir, 1 atazanavir, 1 fosamprenavir, 1 nevirapine/lopinavir/ritonavir
∆3× d4t/lam/kaletra, 1× d4t/nelfinavir/nevirapine, 2× d4t/lam/nelfinavir, 1× d4t/rit/saquinavir, 1× azt/lam/capavirine, 1× azt/lam/indinavir
¤1× D4T/ddI, 1× D4T/lamivudine, 2× AZT/lamivudine/indinavir, 1× AZT/3TC/d4T, 1× D4T/nelfinavir/nevirapine, 1× D4T/ininavir/3TC, 1x ritonavir/saquinavir/D4T/3TC 3× ddI/ritonavir/indinavir/D4T/saquinavir
¥2 patients used medication that might affect cognition (effexor, celexa, ambien)
BOLD characteristics
| Study | HIV/SN | Region | Task | Software | Threshold | Correction M.C. | Results |
|---|---|---|---|---|---|---|---|
| Ances et al. ( | 6/10 | Visual cortex | Checker board | NR |
| Mask used | HIV + showed reduction in mean functional BOLD changes over time and greater inter-subject variance in BOLD measures |
| Ances et al. ( | 24/10 | Motor | Checker board + squeezing | Voxbo | NA (amplitude BOLD signal) | NA | No significant difference in BOLD amplitude between HIV + and − |
| Juengst et al. ( | 31/16 | HRF | Finger tapping | NR | NA (HRF) | NA | No significant difference in mean peak values between HIV + and HIV− |
| Ances et al. ( | 26/25 | Visual cortex | Checkerboard | AFNI |
| Yes, not specified | HIV+ reduced functional changes in BOLD signal |
AFNI analysis of functional neuroimages, BOLD blood oxygenated level dependent, HIV HIV-positive patients, HRF hemodynamic response function, M.C. multiple comparisons, NA not applicable, NR not reported, SN seronegative controls
Whole-brain analysis of difference BOLD signal HIV−/+ patients
| Study | HIV/SN | Network | Task | Software | Statistical thresholding | Result |
|---|---|---|---|---|---|---|
| Caldwell et al. ( | 34/28 | Working memory | Sequential letter task | FEAT | FWE corrected at voxel level | HIV+ greater activation on the simpler attention task but less activation on the working memory task |
| Ernst et al. ( | 31/32 | Attention | Tracking balls | SPM2 | FWE corrected at voxel level | HIV+ more activation in right prefrontal region only with the most difficult task |
| Melrose et al. ( | 11/11 | Semantic event sequencing | Picture sequencing task + object discrimination control | SPM2 | Voxel threshold 0.001 uncorrected, small volume correction | HIV+ less signal change in frontal regions and left caudate and more signal changes in postcentral/supramarginal gyrus |
| Functional connectivity: dysfunction within the basal ganglia and prefrontal cortex and within interactions between these regions | ||||||
| Chang et al. ( | 66/56 | Attention | Tracking balls | SPM8 | FWE corrected at cluster level | HIV+ has load-dependent decreased activation in right temporal region, while HIV− showed load-dependent increase |
| Chang et al. ( | 24/10 | Attention | Tracking balls | SPM2 | FWE corrected at cluster level | HIV+ has greater load-dependent activation in right frontal and cingulate regions |
| Ernst et al. ( | 10/10 | Working memory | Sequential letter task | SPM99b | Voxel threshold 0.001 uncorrected | HIV+ has more BOLD activation in the lateral prefrontal cortex on all tasks |
| Chang et al. ( | 11/11 | Working memory | Sequential letter + number task | SPM99b | Voxel threshold 0.001 uncorrected | HIV+ has greater activation in parietal regions and frontal lobes (lateral prefrontal cortex and supplementary motor area) |
| Maki et al. ( | 7/4 | Memory | Encoding task, recognition task | SPM2 | Cluster corrected (min size >30) uncorrected threshold | Encoding: HIV− more activation in hippocampal and temporal/frontal cortical structures. Recognition: HIV+ more in left superior temporal gyrus, hippocampus, and right insular cortex |
| Chang et al. ( | 18/18 | Attention | Tracking balls | SPM99b | Cluster corrected for M.C. (not specified) | HIV+ decreased activation in the normal visual attention network and increased activation in adjacent/contralateral structures |
| Castelo et al. ( | 14/14 | Memory | Encoding + recognition task | SPM99b | NR | Encoding: no difference. Recognition: HIV+ less activity in right posterior hippocampus, right inferior frontal gyrus, and left lingual gyrus and more activity in lateral frontal and posterior parietal regions |
| Schweinsburg et al. ( | 11/13 | Fronto-striatal | Mental rotation task | AFNI | Cluster corrected multiple thresholds/cluster size | HIV+ had increased activation in areas of the PPC-striato-frontal pathway and in left insular and right occipital cortex and less activation in the anterior cingulate |
| Plessis et al. ( | 18/16 | Ventral-striatal | Reward task | SPM8 | FWE corrected at cluster level | No between group differences |
AFNI analysis of functional neuroimages, BOLD blood oxygen level dependent, FEAT fMRI expert analysis tool, FWE family-wise error, M.C. multiple comparisons, NR not reported, SPM statistical parametric mapping, PPC postero-parietal cortex
ROI analysis of differences BOLD signal HIV+/− patients
| Study | HIV/SN | Network | Task | Software | Corrected for MC? | Pre-specified ROI? | Results |
|---|---|---|---|---|---|---|---|
| Thomas et al. ( | 52/52 | Functional connectivity 5 domains | Resting state | NR | FDR corrected | Yes | HIV+ had less intra- and internetwork correlations in several functional brain networks |
| Chang et al. ( | 24/18 | Visual attention | Tracking balls | SPM2 | Uncorrected | No | HIV+ load-dependent increase in frontal regions when HIV− has load-dependent decrease |
| Maki et al. ( | 7/4 | Episodic encoding | Encoding task, recognition task | SPM2 | Cluster corrected | Yes | HIV+ decreased hippocampal activity during encoding and increased hippocampal activation during recognition |
| Castelo et al. ( | 14/14 | Episodic encoding | Encoding task, recognition task | SPM99b | Not reported | Both | HIV+ had attenuated activation of brain regions known to support episodic encoding (right posterior hippocampus, left and right lingual gyrus, right inferior frontal gyrus) and recruited additional cortical regions |
| Hippocampal activation; no | Yes | HIV+ less activation in bilateral hippocampus | |||||
| Plessis et al. ( | 18/16 | Ventral-striatal reward | Reward task | SPM8 | no | Yes | HIV+ decrease in activation in ventral striatum for anticipating neutral and rewarding cues |
| Ortega et al. ( | 132/49 | Functional connectivity 4 domains | Resting state | FS-FAST | FDR corrected | Yes | HIV+ had lower cortico-striatal functional connectivity. HIV+ cART+ had higher connectivity than HIV+ cART− |
| Ipser et al. ( | 15/15 | Functional connectivity 3 domains | Resting state | AFNI | Not reported | Yes | HIV+ had reductions in connectivity in fronto-striatal regions. |
AFNI analysis of functional neuroimages, FDR false discovery rate, FS-FAST freesurfer functional analysis stream, MC multiple comparisons, NR not reported, ROI region of interest, SPM statistical parametric mapping
BOLD signal differences HIV+/− patients combined with aging effect
| Study | HIV/SN | Network | Task | Software | WB/ROI | Statistical inference | Results |
|---|---|---|---|---|---|---|---|
| Thomas et al. ( | 52/52 | Functional connectivity 5 domains | Resting state functional connectivity | NR | ROI | FDR corrected threshold of 0.05 | Aging causes decrease in intranetwork correlations in DMN and SAL and internetwork correlations between DMN-SAL. No interaction between HIV and aging |
| Ernst et al. ( | 31/32 | Visual attention | Tracking balls | SPM2 | ROI | FWE corrected at voxel level | After 1 year, HIV+ more BOLD signal in right prefrontal and posterior parietal cortices and cerebellum bilaterally. HIV− less BOLD signal after 1 year |
| Chang et al. ( | 66/56 | Visual attention | Tracking balls | SPM8 | WB | FWE corrected at cluster | HIV+ had greater age-related increases in brain activation in right parietal, cingulate and paracentral regions, cerebellar vermis, left frontal, temporal and occipital regions |
| Juengst et al. ( | 31/16 | HRF | Finger tapping | NR | WB | NA (HRF) | No effect or interaction with HIV status for age in mean BOLD peak value |
| Ances et al. ( | 26/25 | Visual cortex | Checkerboard | AFNI | VOI |
| HIV and increasing age independently caused decreases in functional BOLD signal, no interaction |
| Ipser et al. ( | 15/15 | Functional connectivity 3 domains | Resting state | AFNI | ROI | Not reported | Reduction in connectivity in individuals over 50 years, no interaction between age and HIV |
AFNI analysis of functional neuroimages, BOLD blood oxygen level dependent, DMN default mode network, FDR false discovery rate, FWE family-wise error, HRF hemodynamic response function, M.C. multiple comparisons, NR not reported, ROI region of interest analysis, SAL salience network, SPM statistical parametric mapping, VOI volume of interest analysis, WB whole-brain analysis